Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

2 WuXi firms form an antibody-drug conjugate venture

by Rick Mullin
May 22, 2021 | A version of this story appeared in Volume 99, Issue 19

 

WuXi Biologics and WuXi STA, the drug making arm of WuXi AppTec, have formed a joint venture to provide contract production of antibody-drug conjugates (ADCs) and other bioconjugates. WuXi Biologics, which was once part of WuXi AppTec, will invest $120 million in the venture, called WuXi XDC. WuXi STA will invest $80 million. The venture will provide development and manufacture of antibodies, chemical payloads and linkers, and finished conjugated drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.